Impact of Antiretroviral Therapy on Incidence of Pregnancy Among HIV-infected Women in Sub-Saharan Africa: a Cohort Study
Overview
Affiliations
Background: With the rapid expansion of antiretroviral therapy (ART) services in sub-Saharan Africa there is growing recognition of the importance of fertility and childbearing among HIV-infected women. However there are few data on whether ART initiation influences pregnancy rates.
Methods And Findings: We analyzed data from the Mother-to-Child Transmission-Plus (MTCT-Plus) Initiative, a multicountry HIV care and treatment program for women, children, and families. From 11 programs in seven African countries, women were enrolled into care regardless of HIV disease stage and followed at regular intervals; ART was initiated according to national guidelines on the basis of immunological and/or clinical criteria. Standardized forms were used to collect sociodemographic and clinical data, including incident pregnancies. Overall 589 incident pregnancies were observed among the 4,531 women included in this analysis (pregnancy incidence, 7.8/100 person-years [PY]). The rate of new pregnancies was significantly higher among women receiving ART (9.0/100 PY) compared to women not on ART (6.5/100 PY) (adjusted hazard ratio, 1.74; 95% confidence interval, 1.19-2.54). Other factors independently associated with increased risk of incident pregnancy included younger age, lower educational attainment, being married or cohabiting, having a male partner enrolled into the program, failure to use nonbarrier contraception, and higher CD4 cell counts.
Conclusions: ART use is associated with significantly higher pregnancy rates among HIV-infected women in sub-Saharan Africa. While the possible behavioral or biomedical mechanisms that may underlie this association require further investigation, these data highlight the importance of pregnancy planning and management as a critical but neglected component of HIV care and treatment services. Please see later in the article for the Editors' Summary.
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.
Nguyen A, Curtis K, Tepper N, Kortsmit K, Brittain A, Snyder E MMWR Recomm Rep. 2024; 73(4):1-126.
PMID: 39106314 PMC: 11315372. DOI: 10.15585/mmwr.rr7304a1.
Bidzha M, Johnson L, Dorrington R, Ngepah N, Greyling T PLoS One. 2023; 18(4):e0284032.
PMID: 37014906 PMC: 10072469. DOI: 10.1371/journal.pone.0284032.
Eniyew M, Haji Y, Abebe K, Demelash M, Mesfin Y, Embiale A Afr Health Sci. 2023; 22(3):24-33.
PMID: 36910367 PMC: 9993251. DOI: 10.4314/ahs.v22i3.5.
Wariyo A, Oljira L, Golicha W, Dirirsa G BMC Womens Health. 2022; 22(1):548.
PMID: 36572915 PMC: 9793559. DOI: 10.1186/s12905-022-02135-9.
Fertility desire of HIV-positive men and women in public health hospitals.
Wassie S, Marye Yimam S, Birhanu Fentaw T SAGE Open Med. 2022; 10:20503121221124755.
PMID: 36147871 PMC: 9486265. DOI: 10.1177/20503121221124755.